ABBIE, the groundbreaking Integrase-dcas9 fusion protein, is set to transform the field of agriculture by enabling the development of heat-resistant rice and wheat plants, as well as crops with enhanced disease resistance and improved yield. This cutting-edge technology represents a significant advancement over current CRISPR/Cas9 genome editing methods. The global
Artificial intelligence (AI) has opened new possibilities in many fields. The power of AI to increase time to result and efficiency is unparalleled when the AI is tuned correctly, and the appropriate questions are asked and addressed. Gene editing/therapy is no exception and AI has already begun to make big
ABBIE in advancing drug discovery Facebook Twitter Linkedin Exciting news has emerged from the field of gene-editing technology with the first-ever approval of a treatment that utilizes CRISPR. Known as Exa-cel or Casgevy, this groundbreaking therapy has recently received regulatory approval from the U.K. Medicines and Healthcare products. Regulatory Agency
ABBIE is a revolutionary technology that can edit the DNA of living cells with unprecedented precision and efficiency. It has the potential to transform the field of cardiology by enabling new ways of discovering and developing drugs, as well as treating heart disease. In this post, we will explore two of
